Skip to main content

Advertisement

Log in

Urgent surgery for intraperitoneal bleeding from GIST during imatinib therapy

  • Case Report
  • Published:
Clinical Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

The rupture or bleeding of a gastrointestinal stromal tumor (GIST) is a life-threatening adverse event that can happen during imatinib therapy, but few such cases have been reported in the medical literature. Here, we report a case of intraperitoneal bleeding from GIST during imatinib therapy. A 75-year-old man was diagnosed with a large GIST with liver metastasis and admitted to our hospital for abdominal pain on the 13th day of imatinib therapy. The pain disappeared after 7 days of hospitalization; however, the patient complained of diffuse abdominal pain 5 days after discharge. He presented with muscular guarding, and abdominal-pelvic CT demonstrated dense ascites. The tentative diagnosis was peritoneal hemorrhage from GIST, and urgent laparotomy was performed. During the laparotomy, we noted hemoperitoneum of approximately 500 ml; we resected a bulky metastatic tumor on the greater omentum and a primary tumor on the jejunum. The patient took imatinib (400 mg daily) from the ninth postoperative day and underwent monthly checkups for 9 months after the surgery. When GIST patients complain of sudden and severe abdominal pain during imatinib therapy, bleeding from GIST should be considered as a possible adverse effect of imatinib.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Miettinen M, Laseta J. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol. 2003;54:3–24.

    PubMed  Google Scholar 

  2. Demetri GD, Mehren M, Blanke CD, Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–80.

    Article  CAS  PubMed  Google Scholar 

  3. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, et al. European Organisation for Research and Treatment of Cancer. Soft Tissue and Bone Sarcoma Group. Lancet. 2001;358:1421–3.

    Article  PubMed  Google Scholar 

  4. Oku T, Waga E, Sumiyoshi T, Yoshizaki N, Kondo H, Ohira N, et al. A case of primary small intestinal gastrointestinal stromal tumor: an intraperitoneal bleeding from greater omentum metastasis caused by administration of imatinib mesylate. Nippon Shokakibyo Gakkai Zassi (JJSG). 2003;100:863–7. (in Japanese with English abstract).

    Google Scholar 

  5. Hirasaki S, Fujita K, Matsubara M, Kanzaki H, Yamane H, Okuda M, et al. A ruptured large extraluminal ileal gastro-intestinal stromal tumor causing hemoperitoneum. World J Gastroenterol. 2008;14:2928–31.

    Article  PubMed  Google Scholar 

  6. Cegarra-Navarro MF, Corral de la Calle MA, Girela-Baena E, Garcia-Santos JM, Lloret-Eston F. Ruptured gastro-intestinal stromal tumors: radiologic findings in six cases. Abdom Imaging. 2005;30:535–42.

    Article  CAS  PubMed  Google Scholar 

  7. Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST): update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007;5(suppl 2):S1–S29.

    Google Scholar 

  8. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26:626–32.

    Article  CAS  PubMed  Google Scholar 

  9. Yokoyama A, Dairaku N, Kusano M, Koshita S, Shimada N, Yamagiwa T, et al. Two cases of primary unresectable and/or recurrent gastrointestinal stromal tumors of small intestine presenting hemoperitoneum caused by administration of imatinib mesylate. Nippon Shokakibyo Gakkai Zassi (JJSG). 2008;105:1619–26. (in Japanese with English abstract).

    Google Scholar 

  10. Bonvalot S, Eldweny H, Le Pechoux C, Vanel D, Terrier P, Cavalcanti A, et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol. 2006;13:1596–603.

    Article  CAS  PubMed  Google Scholar 

  11. Heinrich MC, Corless C, Demetri GD, Blanke C, Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342–9.

    Article  CAS  PubMed  Google Scholar 

  12. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, Oosterom AT, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumors. Eur J Cancer. 2006;42:1093–103.

    Article  CAS  PubMed  Google Scholar 

  13. Yeh NN, Chen TW, Liu FY, Jan YY, Chen FF. Genetic changes in advanced gastrointestinal stromal tumor (GIST) patients during imatinib mesylate treatment. Langenbecks Arch Surg. 2006;391:615–21.

    Article  PubMed  Google Scholar 

  14. Cruz RJ Jr, Vincenzi R, Ketzer BM, Cecilio AL, Cepeda LA. Spontaneous intratumoral bleeding and rupture of giant gastric stromal tumor (>30 cm) in a young patient. World J Surg Oncol 2008;6:76.

    Google Scholar 

  15. Burkill GJ, Badran M, Al-Muderis O, Meirion Thomas J, Judson IR, Fisher C, et al. Malignant gastrointestinal stromal tumor: distribution, imaging features, pattern of metastatic spread. Radiology. 2003;226:527–32.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tatsuo Kanda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Enomoto, T., Kanda, T., Yajima, K. et al. Urgent surgery for intraperitoneal bleeding from GIST during imatinib therapy. Clin J Gastroenterol 3, 73–77 (2010). https://doi.org/10.1007/s12328-010-0143-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12328-010-0143-3

Keywords

Navigation